Efficacy and Safety of Atorvastatin in Patients with High Risk Coronary Heart Disease

Objective:To study the efficacy and safety of intensive lipid lowering with atorvastatin made in China in patients with coronary artery disease(CAD)with high risk factors.Methods:We enrolled 104 CAD patients admitted to our hospital with high risk factors.All patients were randomized to either low dose of atorvastatin group(n=50,10mg/daily)or large dose of atorvastatin group(n=54,40mg/daily)for 6 months.Total cholesterol(TC),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),triglycerides(TG),serum glucose,hepatic function,renal function,creatine kinase(CK)of the patients were measured before treatment and at 1 month,3 months,6 months,respectively.Results:After six-month treatment,LDL-C,TC,TG levels were reduced by 38.04%,29.37%,20.74%,respectively in the low dose atorvastatin group compared with baseline;whereas reduced by 49.14%,37.69%,26.98%,respectively in the high dose atorvastatin group as compared with baseline level.As for HDL-C,it was increase of 5.98% in low dose atorvastatin group and 3.48% in high dose atorvastatin group.Responder rates were 54.00% in low dose of atorvastatin group and 79.24% in large dose of atorvastatin group.Much more patients in the high dose atorvastatin group achieved LDL cholesterol goal compare with low dose atorvastatin group(P0.01).There were no significant difference in the hepatic function,renal function and CK between both two groups.Conclusion:Atorvastatin at 40mg/d was more powerful in decreasing LDL-C,TC and TG levels,and also more likely to achieve LDL cholesterol goal compared with low dose of atorvastatin,however,safety was similar between the two groups.